Mengis Capital Management’s TherapeuticsMD TXMD Stock Holding History

Mengis Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-204	Closed	-$49K	–	163
2019 Q1	$49K	Sell	204 -180	-47%	-$47.6K	0.03%	122
2018 Q4	$73K	Sell	384 -292	-43%	-$71.2K	0.05%	114
2018 Q3	$221K	Sell	676 -14	-2%	-$4.29K	0.12%	111
2018 Q2	$215K	Buy	+690	New	+$211K	0.13%	114

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mengis Capital Management's TXMD Position: Q2 2019 in Review

Mengis Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 204 shares — an estimated $49K sold.

Mengis Capital Management first reported a position in TXMD in Q2 2018 and held it in 4 quarters. The position peaked at $221K in Q3 2018. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Mengis Capital Management reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
Mengis Capital Management sold 204 TherapeuticsMD shares in Q2 2019, an estimated $49K.
Mengis Capital Management first reported a position in TherapeuticsMD in Q2 2018 and held it in 4 quarters.
Mengis Capital Management's TherapeuticsMD position peaked at $221K in Q3 2018.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Mengis Capital Management's 13F filing for Q2 2019, filed 18 Jul 2019.